Rodman & Renshaw Upgrades Edwards Lifesciences from Underperform to Market Perform

Rodman & Renshaw has published a research report on Edwards Lifesciences Corp EW upgrading the company. In the report, Rodman & Renshaw wrote, "We are upgrading Edwards LifeSciences to a Market Perform rating. Our earlier rating was an UnderPerform with a $66 PT. The stock recently went below our PT and hence the ratings change. Our upgrade is more a reflection of the fact that there will be some relief buying and short covering rather than any true improvement in fundamentals." Rodman & Renshaw upgraded Edwards Lifesciences from UnderPerform to Market Perform with a price target of $66.00.